Jaye Viner, M.D., has been appointed chief medical officer and executive vice president of Curis, Inc. Dr. Viner will be responsible for the leadership of Curis’ clinical development strategy and development efforts for its pipeline of proprietary drug candidates. Also, Tania Chander, Pharm.D., has been named vice president of product development, responsible for project leadership throughout the product development process.
 
Dr. Viner previously served as a medical director at Millennium: The Takeda Oncology Company, where she oversaw the implementation of a global Phase III study of MLN9708, an oral proteasome inhibitor being developed for multiple myeloma. Prior to Millennium, Dr. Viner was at MedImmune, (AstraZeneca), where she was responsible for the planning and execution Phase I and II studies testing targeted cancer drug candidates. Dr. Viner has also held senior leadership positions at the National Cancer Institute and the National Institutes of Health.
 
Dr. Chander joins the company from MedImmune, LLC (AstraZeneca), where she held several positions of increasing responsibility across multiple therapeutic areas. Most recently, she was associate director, Product Development Team Lead, where she provided leadership to oncology product teams on strategy and clinical development for various oncology drug candidates.
 
“We are delighted to have Drs. Viner and Chander join the Curis team as we seek to implement the next stage of our corporate development strategy. These strategic appointments further Curis’ mission to strengthen its clinical oncology capabilities,” said Ali Fattaey, Curis’ president and chief operating officer. “We are highly encouraged by the prospects of our proprietary clinical-stage drug candidates and Jaye and Tania’s joining coincides with Curis’ strategic transition and focus on innovative and effective clinical development.”